Kajal Shah, MD
Endocrinology, Diabetes & Metabolism · Utto, TXNPI 1619418985
Payments from drug & device makers
Across 93 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$444
- Lilly USA, LLC$257
- AbbVie$141
- Boston Scientific$134
- Tandem Diabetes Care, Inc.$129
- Amgen$104
- plus $976 from 24 others
What the payments were for
- Food & beverage$2,184100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $444 |
| Lilly USA, LLC | 11 | $257 |
| AbbVie | 6 | $141 |
| Boston Scientific | 1 | $134 |
| Tandem Diabetes Care, Inc. | 4 | $129 |
| Amgen(2 entities) | 6 | $104 |
| Medtronic | 4 | $86 |
| Dexcom, Inc. | 4 | $86 |
| BETA Bionics, Inc. | 3 | $81 |
| Insulet Corporation | 4 | $79 |
| Corcept Therapeutics | 4 | $71 |
| AstraZeneca(2 entities) | 4 | $65 |
| Radius Health, Inc. | 3 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| Boehringer Ingelheim | 2 | $51 |
| Bayer | 3 | $49 |
| Soleno Therapeutics, Inc. | 1 | $34 |
| Chiesi USA, Inc. | 2 | $33 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Antares Pharma, Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBOLD Fibered$134
- Wegovy$101
How this compares
$2,184 in reported general payments places this provider in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 117 | $140,516 |
| OzempicSemaglutide | 87 | $100,106 |
| TymlosAbaloparatide | 15 | $61,213 |
| TrulicityDulaglutide | 51 | $56,537 |
| JardianceEmpagliflozin | 16 | $20,441 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $18,473 |
| FarxigaDapagliflozin Propanediol | 12 | $13,871 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $13,293 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $9,149 |
| XyostedTestosterone Enanthate | 14 | $9,007 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $5,808 |
| SynthroidLevothyroxine Sodium | 64 | $4,278 |
| Novolog FlexpenInsulin Aspart | 14 | $2,461 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,064 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $257 | $197,053168 claims |
| Novo NordiskOzempic | $444 | $100,10687 claims |
| Radius Health, Inc.Tymlos | $64 | $61,21315 claims |
| Boehringer IngelheimJardiance | $51 | $20,44116 claims |
| AstraZenecaFarxiga | $65 | $13,87112 claims |
| Antares Pharma, Inc.Xyosted | $23 | $9,00714 claims |
| AbbVieSynthroid | $141 | $4,27864 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $1,294120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Utto
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.